TearSolutions key facts
as of Oct 2026- Developer of a peptide therapy designed for the treatment of signs and symptoms of dry eye in primary sjögren's syndrome patients.
- TearSolutions is valued at approximately $280.0M as of Oct 2026 (last reported valuation).
- It has raised $44.1M across 11 recorded rounds; the latest was Seed Round ($517K) in Oct 2025.
- Notable investors include Virginia Innovation Partnership Corporation, Virginia Venture Partners, CAV Angels, University of Virginia, Dave Metzak — 13 tracked in total.
- TearSolutions has filed 13 Form Ds with the SEC since 2014, most recently Oct 2024 ($12.7M sold to 80 investors).
- Status: Privately Held (backing).
TearSolutions's last reported valuation, Nov 2024. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch TearSolutions: the Monday email on marks, rounds and moves
TearSolutions funding rounds
11 roundsWho backs TearSolutions
13+TearSolutions valuation
TearSolutions's last reported valuation was $280 million in Nov 2024. No priced round, secondary trade or fund mark has surfaced since.
How much has TearSolutions raised?
TearSolutions has raised $44.1 million across 11 recorded rounds since 2014. The largest was an $8.1 million early-stage round in Dec 2017; the most recent was a $517,000 seed round in Oct 2025.
TearSolutions has filed 13 Form Ds with the SEC since 2014, most recently in Oct 2024 ($12.7 million sold to 80 investors).
TearSolutions investors
13 investors are on record for TearSolutions, including Virginia Innovation Partnership Corporation, Virginia Venture Partners, CAV Angels and University of Virginia. The seed round in Oct 2025 drew 12 investors.
About TearSolutions
Developer of a peptide therapy designed for the treatment of signs and symptoms of dry eye in primary sjögren's syndrome patients. The company's product helps patient preserves all of the biological activity of a naturally occurring tear protein by introducing a short stable peptide that can be produced at scale and restore basal tearing without irritation and heal the corneal surface of the eye, providing patients with rapid improvement in corneal health and a reduction in symptoms of dry eyes.
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2013
- Employees
- 10
- Website
- tearsolutions.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.